This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
ACR50: 28% vs 10% in the XELJANZ and placebo group, respectively (p<0.001)1
ACR70: 17% vs 5% in the XELJANZ and placebo group, respectively (p<0.004)1
Statistical testing was performed comparing placebo with XELJANZ up to three months.
XELJANZ in combination with methotrexate (MTX) is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.5
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
ACR=American College of Rheumatology; BID=twice daily; csDMARD=conventional synthetic disease-modifying antirheumatic drug; HAQ-DI=Health Assessment Questionnaire-Disability Index; IR=inadequate responder; mTSS=modified Total Sharp Score; PsA=psoriatic arthritis; Q2W=once every two weeks; SC=subcutaneous; TNFi=tumour necrosis factor inhibitor.
Learn more about the XELJANZ safety profile in PsA
Learn about dosing in PsA
Find out more about how XELJANZ works
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023